Dorothea Rudolph

Medicine · Health Sciences

20h-index4.4kcitations100works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(36), Microtubule and mitosis dynamics(32), Biochemical and Molecular Research(19), Protein Degradation and Inhibitors(14), Cancer Research and Treatments(10)

Publications100 total

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer
Science Translational Medicine·2025· 3 citedOpen Access
Supplementary Figure 1 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 8 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Data from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 6 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 2 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 10 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Tables 1-5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 7 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 1 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 2 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 9 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Molecular Cancer Therapeutics·2024· 14 citedOpen Access
Table S12 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Darryl B. McConnell(22), Norbert Kraut(22), Daniel Gerlach(16), Andreas Gollner(13), Jens Quant(12), Pilar Garin‐Chesa(11), Ulrike Weyer-Czernilofsky(11), Jesse Lipp(11), Mark Pearson(10), Michael Gmachl(10), Fabio Savarese(10), Matthias Treu(10), Antonio Tedeschi(10), Tobias Wunberg(9), Guido Boehmelt(9), Irene C. Waizenegger(9), Patrizia Sini(9), Christopher P. Vellano(9), Timothy P. Heffernan(9), Lorenz Herdeis(8)